Aligned Genetics얼라인드
238120 · KOSDAQ · ₩238120 · 얼라인드
₩2,435▼ ₩90 (3.56%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩16B | ₩16B | ₩15B | ₩14B | ₩12B |
| Cost of sales | ₩4.8B | ₩4.6B | ₩4.5B | ₩5B | ₩4.4B |
| Gross profit | ₩11B | ₩11B | ₩11B | ₩8.8B | ₩7.3B |
| Operating income | ₩2.4B | ₩2.8B | ₩3.3B | ₩2.8B | ₩2.2B |
| Net income | ₩2.9B | ₩4.1B | ₩3.2B | ₩2.3B | ₩5.5B |
| Net income to shareholders | ₩2.9B | ₩4.1B | ₩3.2B | ₩2.3B | ₩5.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩58B | ₩44B | ₩41B | ₩37B | ₩34B |
| Current assets | ₩23B | ₩26B | ₩22B | ₩20B | ₩18B |
| Cash and equivalents | ₩15B | ₩10B | ₩15B | ₩11B | ₩6.1B |
| Total liabilities | ₩21B | ₩8.8B | ₩9.6B | ₩8.1B | ₩7.5B |
| Current liabilities | ₩4.5B | ₩1.9B | ₩5.2B | ₩1.3B | ₩1.4B |
| Borrowings | ₩12B | ₩2.4B | ₩3.9B | ₩3.9B | ₩3.9B |
| Total equity | ₩37B | ₩35B | ₩31B | ₩29B | ₩27B |
| Shareholders' equity | ₩37B | ₩35B | ₩31B | ₩29B | ₩27B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩3.6B | ₩3.1B | ₩2.8B | ₩2.2B | ₩136M |
| Capital spending | — | ₩258M | ₩879M | ₩2B | ₩4.9B |
| Free cash flow | ₩3.6B | ₩2.8B | ₩2B | ₩221M | −₩4.7B |
Consolidated where available. Amounts in won.
Also known as: Aligned Genetics / 얼라인드 / 238120 / KRX:238120
Source: KRX statistical information